{"name":"Orient Europharma Co., Ltd.","slug":"orient-europharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"2ccPA","genericName":"2ccPA","slug":"2ccpa","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"2ccPA","genericName":"2ccPA","slug":"2ccpa","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWE5PeDl6VGpTS2dfMDZUcVk1STN4LUhpdkJwS19NX0RCamlac2NzbGw5N3hkdTg1Q2xUd1VHLWZTQjdpLXlIdXhycFIycnMwSWxxRXlVcDNMblQtTEVnRjlSXzdvNHVzUThNN3VBMExMRnB0QmlhUmRWSXh0Y1RiZnhka3ZNTmtHekcydVJoSXNGS3EzM2RBNExyRVhuMTh0SzdFc1JGdzBKRVNTNVRnamlTQkYxQXlQOTczUzl3aEZ2WDZ1WUJfZllBb0diSWZmMDJBUFpsdzNIak9UcWRNREYzdll2SjJWT2ZORFBxQkdSWk1tRGww?oc=5","date":"2026-03-03","type":"deal","source":"Citeline News & Insights","summary":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","headline":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQRTM0dXB4Sm9udzY0TlBZWWhYOWw4cVI5YXVUcFc0NU5mQnhjNHM5YjhFdkxUOC1Gc3hxOWdNM3BhQXF1X3J4NXhDU1ZKckVNVEVkVlU5VE4wTUNqa3MxQ1cxbmhfeDRfZ1I0REZfZjZ1YkpZbFZqaDkwVHNGOXI1NVNxdVBiOFlqclhwRmN2d0ZHekRIMzBCREp6cTg5TWtOVl9LenpHckpYY0psTkVXeDV5UGhXaktFR3dUZXBJdHVoWkNkanBLaExaZjhfZ1hpTnlDMDkzNkN4U20xb2NLTWpsT3NnUXpXTDh5aU83SUFlTXhwZUpXeVBNMmRNWm9sYVotelFSQnRFX3dUd1htaTlqT3lCUloyc3BaVVl1THZkbld2MHZFWTlTbkYxZmkwTXB1aWVFUFY5RHFUbXc?oc=5","date":"2026-02-25","type":"pipeline","source":"GlobeNewswire","summary":"George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia - GlobeNewswire","headline":"George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient Eur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQY1RRd1U2aFF4ajgyTlhfN3M0bW9rY2tSb2ZMSEthVzFsNHBaLTVQTUxvNjVKTWtDdS1ZVHMyeHZBZHdaakJobHBoY2NxaVAyNk9YM210X3RkNzRuczlMNDdjU1kwb09iWlB2UXZjMURwVE85aXRCd25hTnNLelJjejYycVRYWmhnYzgteE5IcHA5Tk9hWjlaSk0xTFowQk1JS1JLN0lmZ0k3Q1J2VWNJQg?oc=5","date":"2023-03-29","type":"deal","source":"Contract Pharma","summary":"OncoVent, Orient EuroPharma Enter License Agreement for Oregovomab - Contract Pharma","headline":"OncoVent, Orient EuroPharma Enter License Agreement for Oregovomab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZXU1Y0phNzg4LXltaTV6QWQ4ZnMtajRBQ0k1SFZRYnJrUWw5LXNNenlUUWRXSVRmelZuNnRqcGtYdjZmU3VieVl0aUtmZVlUSWNSRGEzUXdjUm9IcWNiMkJxTExfZWM2VlhoV3MyMGYxai1KdEg4OUUxX3FqVEl6VF94blU2eF9mZXN0N3NVd3hDcmc?oc=5","date":"2023-01-12","type":"earnings","source":"全球醫療採購網","summary":"Taiwan business watch 2022: Biomedical sector top 20 by revenue and segment - 全球醫療採購網","headline":"Taiwan business watch 2022: Biomedical sector top 20 by revenue and segment - 全球醫療採購網","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBvYkRJYzhwT25fQW9GU1FzUU1fSHFfTFZuWm9sSXVCSjZRd0RSRk51VWMzMU5BRUhRdjVKamlwdldnM3ZaSzJxcFg4UzR1VldvR3JkV1ZHSQ?oc=5","date":"2017-09-08","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Orient EuroPharma Co., Ltd. (4120.TWO) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Orient EuroPharma Co., Ltd. (4120.TWO) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNb0dYXzRCV3hjUWZ5dmNfMFRRUURBcTQ2T3ZsUFRFSno5Q3B5a3hhSFlacFNCbmdaT2VoeV9pZVVQTy1KemdsUVhqSy1sUzVXZFcteXZJR3A1SG5fakxoY2VLeEFUQWJmLXlYXzkwR2pkUVRMMG0yRmhabjUyYWI4UW1QRzJhV0dtZ2tidkFUNDhMeFBuSWxncGVxa0pjNWE4eUxjWjh1a3JmV3lNQXdUcHlkX2pwdExyYUc5Q0lUa0xQMDh5cTBHSW5MSXgyVS1OTlM5b1pLR1NZR0E5WXpsczhKMS1OY2hRX09oUDZn?oc=5","date":"2012-08-14","type":"pipeline","source":"drugoffice.gov.hk","summary":"Medicine recalls - drugoffice.gov.hk","headline":"Medicine recalls","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWjRuY1pkcHJFOEsteEQ4YS02eFhqdC0weTZaMGpULVJnMThEOHRNWk9uYXhYUkZEQ1ZYRlJUTEdOZE9BRExUWk1xR0E2ZUJleDUxRkJNam0xR09DRENBSk5HYjhCZ2pSVWdZR1lfS0xBUU9iZjdlSWc4eFVxNXRoY2cyUjlFS3hJVG5reTlUekFjNmNvMEkyVzRsa9IBoAFBVV95cUxNRXhWNUJSVm8wZTFVLUhocV85UGFJdndZS0huSTNpbVc3U3ZUYmVPWGdfd1BOby1HTDZ0a1pwaHlJTTlvQWR1YnYzbmozSklfcXVBbUpNSHZZUE5wR3U2c0dfZUpCd3VsM2VLSnZVZlh6REw4RjZtOEMxMjkzMmQ0VWVDZmdndUZ4R1NVYlJiRk9rMkJxSldLdEU1S3BQNkdy?oc=5","date":"2007-08-27","type":"pipeline","source":"Business Standard","summary":"Ajanta Pharma plans SEZ - Business Standard","headline":"Ajanta Pharma plans SEZ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}